PASG Company Profile and Key Details

Q: Who are the executives of PASG?

Ms. Simona KingChief Financial Officer & Corporation Sec.David Weinstein M.D.Senior Vice President of Clinical Devel.Dr. William Chou M.D.Pres, Chief Executive Officer & DirectorMr. Edgar B. Cale Esq., J.D.Gen. Counsel & Company Sec.Gregory FuestVice President of Global Commercial Strategy & MarketingDr. Mark Forman M.D., Ph.D.Chief Medical OfficerDr. James M. Wilson M.D., Ph.D.Co-Founder & Chief Scientific AdvisorMr. Alexandros Fotopoulos MBA, MScChief Technical OfficerMr. Stuart M. HendersonSenior Vice President of Corporation Devel. & Investor RelationsDesiree Luthman D.D.S.Senior Vice President of Global Regulatory AffairsDr. Desiree Luthman D.D.S.Senior Vice President of Global Regulatory AffairsMs. Kathleen BorthwickSenior Vice President of Fin., Principal Accounting Officer & Interim Chief Financial OfficerEden FucciSenior Vice President of Technical Operations

NASDAQ : PASG

Passage Bio

$12.67

-0.1-0.78%

Open: 3:49 PM

60.3

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Passage Bio, Inc. (PASG) stock declined over -0.78%, trading at $12.67 on NASDAQ, down from the previous close of $12.77. The stock opened at $13.55, fluctuating between $11.88 and $13.55 in the recent session.

Stock Snapshot

12.77

Prev. Close

40.27M

Market Cap

11.88

Day Low

-0.87

P/E Ratio

-14.62

EPS (TTM)

-1.43

Cash Flow per Share

13.55

Open

3.18M

Number of Shares

13.55

Day High

90.2%

Free Float in %

2.03

Book Value

87.08K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	12.76	13.55	12.01	12.77	66.3K
Jan 16, 2026	14.32	14.80	12.50	12.87	39.57K
Jan 15, 2026	15.50	16.12	14.28	14.28	56.67K
Jan 14, 2026	18.00	18.00	14.55	15.16	39.93K
Jan 13, 2026	18.00	18.01	13.33	14.27	100.72K
Jan 12, 2026	19.95	19.95	17.27	17.91	82.37K
Jan 09, 2026	18.00	20.00	17.43	19.85	179.17K
Jan 08, 2026	17.78	18.50	16.67	18.33	61.85K
Jan 07, 2026	18.58	19.25	17.01	18.04	100.77K
Jan 06, 2026	15.39	19.22	15.39	18.46	267.79K
Jan 05, 2026	13.32	16.70	13.31	16.11	387.81K
Jan 02, 2026	11.80	12.28	11.37	11.69	27.43K
Dec 31, 2025	10.45	11.83	10.45	11.80	43.22K
Dec 30, 2025	10.35	11.00	10.35	10.70	14.54K
Dec 29, 2025	10.27	11.50	9.56	11.08	42.1K
Dec 26, 2025	10.99	11.03	10.49	10.86	21.46K
Dec 24, 2025	9.95	11.32	9.73	10.89	70.08K
Dec 23, 2025	9.80	10.03	9.47	10.02	21.67K
Dec 22, 2025	9.53	10.44	9.24	9.99	19.75K
Dec 19, 2025	9.15	9.93	9.15	9.59	75.09K

Contact Details

Philadelphia, PA 19103

United States

https://www.passagebio.com 267 866 0311

About Company

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Passage Bio, Inc. (NASDAQ:PASG) closed at $12.67 USD, losing -$0.10 (-0.78%) from the previous close of $12.77. The stock is currently mid-range between its 52-week high and low $5.12 and $20.00. With a market capitalization of about $40.27 million, Passage Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.76). Key stats such as the average daily volume over the past year has been around 59.06 thousand shares, in line with its 52-week average. Headquartered in Philadelphia, PA, Passage Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William Chou, the company employs approximately 60 people and listed since February 28, 2020. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -7.01%, SMA50 18.92%, SMA200 57.14%). The stock’s 14-day RSI is 48.48 (neutral), while the ATR of 1.89 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.15% below its high and over 149.22% above its low. Average 10-day trading volume of 64.26 thousand shares is in line with the 3-month average of 58.99 thousand, indicating normal recent market interest.

Valuation Metrics

Passage Bio, Inc. trades at a P/E ratio of -0.88, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.28 suggesting the stock is closer to book value. The P/FCF stands at -1.19, also above market averages.

Dividend & Fair Value

Passage Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.01. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Passage Bio, Inc. generated EPS of -$14.46 over the past year. Five-year average earnings growth is -1.48%. Wall Street analysts project EPS growth of 50.89% annually over the next five years. The latest quarter delivered EPS of -$2.44. The next quarter is forecast at -$2.57. Next year's EPS is expected at $30.65. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $6.00. The high target offers 424.67% upside. The low target suggests -53.01% downside. The mean target is $25.00. This offers 95.77% upside. Passage Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by -7.58%. The prior quarter beat by -26.0%. Over the last six quarters, Apple has recorded several small beats. These include -16.13% in August 08, 2024.

Shareholding & Insider Activity

Passage Bio, Inc. has 3.18 million shares outstanding. The public float is 2.87 million shares, elevated short interest at 4.12% of float. This equals 97.13 thousand shares. The short ratio is 1.12 days. Institutional investors hold 54.62% of the float. Insiders own 0.21%. OrbiMed Capital GP VII LLC holds 6.54 million shares, ORBIMED ADVISORS LLC has 6.07 million shares and Frazier Life Sciences IX, L.P. has 5.01 million shares. Over the past six months, insider transactions show net buying. They sold 6.14 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Passage Bio has not generated any revenue. Returns are negative, with ROA at -67.80% and ROE at -91.71%.
On valuation metrics, Passage Bio trades at a P/E of -0.88, P/S of 0.00 and P/B of 1.28. The current ratio is 2.51 and quick ratio is 2.51. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -378.11 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.78, supported by a cash flow-to-debt ratio of -1.38.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Passage Bio posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $3.72M (margin 0.00%). Operating income was - $100.14M (margin 0.0%). Net income was- $102.06M (EPS - $1.86).
The company ended the quarter with $114.29M in cash and short-term investments, a total debt of $26.29M, and net debt of $4.59M. Total assets were $150.55M, with equity of $111.28M. Financials further reflected weakness, with operating cash flow of - $78.26M, free cash flow of - $78.41M, and capital expenditures of - $146.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Passage Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 19.19%, with price expected at $15.22 by February 03, 2026, within a range of $12.76 to $17.61 3-Month Outlook: Projected rise of 35.4%, reaching $17.29 by April 16, 2026, with a range of $16.47 to $18.13. 1-Year Outlook: Projected gain of 260.45%, with price at $46.03 by January 15, 2027, within a range of $28.60 to $63.32.

Key Takeaways

Passage Bio, Inc. (NASDAQ:PASG) shares are flat 8.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Passage Bio, Inc. trading at a premium to the broader market with a P/E of -0.88. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.31, suggesting 59.04% upside. Our AI forecast model points to short-term strength (19.19% over two weeks), a medium-term rise (35.4% over three months), and a longer-term gain (260.45% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Passage Bio, Inc. (PASG) stock price?

Passage Bio, Inc. (NASDAQ: PASG) stock price is $12.67 in the last trading session. During the trading session, PASG stock reached the peak price of $13.55 while $11.88 was the lowest point it dropped to. The percentage change in PASG stock occurred in the recent session was -0.78% while the dollar amount for the price change in PASG stock was - $0.10.

PASG's industry and sector of operation?

The NASDAQ listed PASG is part of Biotechnology industry that operates in the broader Healthcare sector. Passage Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PASG?

Ms. Simona King
Chief Financial Officer & Corporation Sec.
David Weinstein M.D.
Senior Vice President of Clinical Devel.
Dr. William Chou M.D.
Pres, Chief Executive Officer & Director
Mr. Edgar B. Cale Esq., J.D.
Gen. Counsel & Company Sec.
Gregory Fuest
Vice President of Global Commercial Strategy & Marketing
Dr. Mark Forman M.D., Ph.D.
Chief Medical Officer
Dr. James M. Wilson M.D., Ph.D.
Co-Founder & Chief Scientific Advisor
Mr. Alexandros Fotopoulos MBA, MSc
Chief Technical Officer
Mr. Stuart M. Henderson
Senior Vice President of Corporation Devel. & Investor Relations
Desiree Luthman D.D.S.
Senior Vice President of Global Regulatory Affairs
Dr. Desiree Luthman D.D.S.
Senior Vice President of Global Regulatory Affairs
Ms. Kathleen Borthwick
Senior Vice President of Fin., Principal Accounting Officer & Interim Chief Financial Officer
Eden Fucci
Senior Vice President of Technical Operations

How PASG did perform over past 52-week?

PASG's closing price is 149.22% higher than its 52-week low of $5.12 where as its distance from 52-week high of $20.00 is -36.15%.

How many employees does PASG have?

Number of PASG employees currently stands at 60.

Link for PASG official website?

Official Website of PASG is: https://www.passagebio.com

How do I contact PASG?

PASG could be contacted at phone 267 866 0311 and can also be accessed through its website. PASG operates from One Commerce Square, Philadelphia, PA 19103, United States.

How many shares of PASG are traded daily?

PASG stock volume for the day was 87.08K shares. The average number of PASG shares traded daily for last 3 months was 59.06K.

What is the market cap of PASG currently?

The market value of PASG currently stands at $40.27M with its latest stock price at $12.67 and 3.18M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	60
Beta	1.76
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PASG Company Profile and Key Details

Passage Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics